Should You Buy CVS Health Stock At Around $80 Levels?

+11.00%
Upside
79.43
Market
88.17
Trefis
CVS: CVS Health logo
CVS
CVS Health

[Updated: 8/9/2021] CVS Stock Update

CVS Health (NYSE: CVS) recently reported its Q2 results, which were better than Trefis’ as well as the street estimates. The company reported sales of $72.6 billion, up 11% y-o-y, and it was comfortably above our forecast of 70.3 billion.  The sales growth was visible across all the segments, with growth in prescription volume as well as footfall at the store. CVS administered 17 million Covid-19 vaccines and over 6 million Covid-19 tests during the quarter, bolstering its overall sales growth.

Looking at the bottom-line, the company reported adjusted earnings of $2.42 per share, down 9% y-o-y, but well above our forecast of $2.09 and consensus estimate of $2.06. The y-o-y decline was expected given that the company in Q2 2020 incurred very low benefits costs, due to fewer elective surgeries in the lockdown period. For perspective, benefit costs as a percentage of premium income stood at 84% in Q2 2021, compared to just 69% in the prior year quarter. The overall margins are likely to see some pressure going forward, as the company expects an increase in employee wages. Also, the number of Covid-19 vaccine and tests administered are expected to decline with a rise in overall vaccination rate in the U.S.

Relevant Articles
  1. Should You Pick CVS Stock At $75 After A 6% Fall This Year?
  2. Is CVS Health Stock Undervalued At $70?
  3. Will CVS Health Stock Recover To Its Pre-Inflation Shock Highs of $110?
  4. Higher Costs To Weigh On CVS Health’s Q2?
  5. Should You Buy CVS Stock At $70?
  6. Will CVS Stock Rise Post Q1?

We have updated our model following the Q2 release. We forecast sales to be $285 billion for the full-year 2021, up 6% y-o-y, and closer to the high-end of the company’s provided guidance of $281 – $285 billion. We estimate adjusted EPS to be $7.75, compared to our earlier estimate of $7.65, and at mid-point of the company’s provided range of $7.70 – $7.80 per share. Given the changes to our forecast, we have revised our CVS Health Valuation at $96 per share, based on $7.75 expected EPS and maintaining a 12x P/E multiple for 2021. Although the revised valuation marks only a modest 4% growth from our prior estimate, it reflects a premium of over 18% to the current market price of $81, implying that the stock has more room for growth.

 

[Updated: 8/3/2021] CVS Q2 Earnings Preview

CVS Health (NYSE: CVS) is scheduled to report its Q2 2021 results on Wednesday, Aug 4. We expect CVS Health to likely post revenue and earnings slightly above the street expectations, primarily driven by Covid-19 vaccine administration. The company will also benefit from a recovery in its pharmacy management business. While we expect the company to navigate well in Q2 based on these factors, a rebound in total procedure volume will likely result in higher benefit costs, weighing on the overall earnings growth, in our view. Furthermore, our forecast indicates that CVS’ valuation is $92 per share, which is 12% above the current market price of around $82, implying CVS stock has more room for growth. Our interactive dashboard analysis on CVS Health’s Pre-Earnings has additional details.

(1) Revenues expected to be slightly above the consensus estimates

Trefis estimates CVS Health’s Q2 2021 net revenues to be around $70.3 billion, slightly above the $70.1 billion consensus estimate. Revenue growth is expected to be led by the Covid-19 vaccination, which CVS is administering in over 8,000 locations. However, given the rise in overall vaccination rate, the demand for testing has come down. As such, CVS’ revenues from administering the Covid-19 testing is expected to see a sequential decline. On the Aetna side, the company will likely continue to add new Medicaid members. Also, given an increase in hospital visits, the company’s pharmacy business likely rebounded in Q2.  Our dashboard on CVS Health’s Revenues offers more details on the company’s segments.

2) EPS also likely to be just above the consensus estimates

CVS Health’s Q2 2021 adjusted earnings per share (EPS) is expected to be $2.09 per Trefis analysis, compared to consensus estimate of $2.06. CVS Health’s adjusted net income of $2.7 billion in Q1 2021 reflected an 8% rise from its $2.5 billion figure in the prior-year quarter. This can be attributed to higher revenues and an expansion of margins. For the full-year 2021, we expect the adjusted EPS to be $7.65, compared to $7.50 seen in 2020.

(3) Stock price estimate 12% higher than the current market price

Going by our CVS Health’s Valuation with an EPS estimate of $7.65 and a P/E multiple of 12x in 2021, this translates into a price of $92, which is 12% above the current market price of around $82. While the 12x figure compares with levels of 9x – 10x seen over the recent years, we believe the P/E multiple will likely increase with margin expansion and better earnings growth over the coming years.

Note: P/E Multiples are based on Share Price at the end of the year and reported (or expected) Adjusted Earnings for the full year.

While CVS stock may rise in the near term, 2020 has created many pricing discontinuities which can offer attractive trading opportunities. For example, you’ll be surprised how counter-intuitive the stock valuation is for Flir Systems vs. CVS Health.

See all Trefis Price Estimates and Download Trefis Data here

What’s behind Trefis? See How It’s Powering New Collaboration and What-Ifs For CFOs and Finance Teams | Product, R&D, and Marketing Teams